Furthermore, teclistamab can recruit CD3+ T cells to the vicinity of BCMA-positive clonal plasma cells, enhancing targeted cytotoxicity against myeloma cells (6). This evidence concerns the gene TNFRSF17 and plasma cell myeloma.